Epic’s test for AR-V7 is offered by its partner, Exact Sciences, under the brand Oncotype DX AR-V7 Nucleus Detect®. This test is Epic’s first test that is commercially available and reimbursed by Medicare. The Oncotype DX AR-V7 Nucleus Detect test is a liquid biopsy assay that analyzes circulating tumor cells in a patient's blood. No intrusive or complicated procedures are required. The AR-V7 Nucleus Detect test identifies whether your tumor will respond to androgen receptor (AR)-targeted therapies—such as XTANDI® or ZYTIGA®—or whether you should consider chemotherapy or other therapies. The results will say either tumor is AR-V7 positive (AR-V7+) or AR-V7 negative (AR-V7-). An AR-V7+ result means your tumor will not respond to AR-targeted therapies and you should consider other treatments instead.
Prostate Cancer
AR (Androgen receptor)
Xtandi (enzalutamide capsule), abiraterone acetate
Liquid biopsy